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S_q Randomised cinical trials are essential for the objective evaluation of different treatment stratei
in cancer. However, in the field of oncology, very few of the eligible patients are entered into trials, and most
treatments have only been tested on a small percentage of patients. For doctors, a major deterrent to
participating in tra is the lack of resources - particularly tme, but often also the local facilities. Tlhis report
suggests that patients themselves are willing to take part in chnical research, and are attracted by being treated
by a doctor with a seciaist interest in the disea and encouraged by the possibility that their progress will be
monitored closely. With the recent NHS changs, it is timely for the Department of Health and other national
health departments to consider carefuly what can be done to ensure that no new treatments are adopted
without effectie evaluation. This wil reqmre departments of health to identify and implement ways to
facilitate accrual of appropiate numbers of patients onto research protocols (whether non-randomised phase I
or phase n studies or lare, multicentre phase HIl trials) over short time periods.
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Most advances in oncology are achieved by a series of small
incremntal improvements which, because they are small,
may not be obvious. For example, numerous studies of
adjuvant therapy in breast cancer have failed to demonstrate
a benefit which convinces the majority of breast surgeons,
but the Early Breast Cancer Trialists' Collaborative Group
overview ofadjuvant treatment (Early Breast Cancer Tralists
Collaborative Group, 1992), involving nearly 75 000 women,
showed a highly signifint reduction in the annual death
rate from the disease. This information, because of the
numbers of women involved, is reliable and did persuade
most surgeons and, if translated into routine clnical practic
worldwide, would save many thousands of lives each year.
Phase I and II studie of new treatments, however, because
they are carried out on very small numbers of carefully
selected patients, sometimes suggest that the new drug or
schedule can confer dramatic improvements wch subse-
quently turn out not to be real (Tannock, 1992). The only
reliable way to detect small but important differences (Ant-
man et al., 1985), or to confirm whether new treatments
really are effective, is to test the new treatments against
standard therapy in randomised clinical trials.
In recent years it has become clear that such studies must
be large in order to detect the small or moderate differences
between treatments that can rlsticaly be expeted. Fur-
thermore, the accrual rate must not be so slow that the
results are overtaken by changing conditions or practice.
Currently, the number of patients with cancer who enter
clinical trials represents only a tiny percentage of the
available patient pool (Friedman and Cain, 1990); trials rely
on the minority of clinicians who have a parficular interest in
clinical research to provide the majority of patients. The UK
Coordinating Committee on Cancer Research (UKCCCR)
AXIS trial in colorectal cancer has only recruited 600
patients per year, these are entered from about 14 000 eligi-
ble, new case of colorectal cancer each year (S Stenning,
personal communication). Childhood cancers and
leukaemias, and certain rare solid tumours, are the excep-
tions in that a large proportion of these patients are entered
into trials. It is becoming increasingly accepted that studies
need to be undertaken on a national and international, rather
than local, basis to achieve the necessary patient numbers.
There are many reasons why the accrual of patients into
clinical trials is so low (Gotay, 1991). A major factor may be
local difficultis in the availability of appropriate resources.
For example, there may be limited radiotherapy services
available, or difficulties in meeting the costs ofexpensive new
drugs. Another resource in short supply may be doctors'
time; doctors may be reluctant to enter their patients into
large randomised trals because they lack the tme to explain
the trial and the concept of randomisation to the patients
and to obtain informed consent, and because of the extra
effort required to record the ne:ssary data (Smyth et al.,
1994). There may not be a suitable trial asking what the
clinician considers to be an important and relevant question.
Many doctors are concered that the need to admit publicly
that they do not know the best treatment can damage the
doctor-patient relationship (Angell, 1984; Taylor et al.,
1984). For young doctors, it may be a career advantage to
undertake small studies which provide first author publica-
tions rather than be one author among many of a multicen-
tre trial, although in general these small studies do little to
advance medical knowledge.
The difficulties faced by clnicians in contributing to ran-
domised clinil trials remain a problem which must be
addressed by the providers of health care. If these can be
resolved, the issue of patients' willingness to participate will
become a key determinant of accrual. Very little is known
about what encourages patients to accept or discourages
them from accepting, an invitation to take part in a ran-
domised clinical trial. Do they see themselves as willing
volunteers entering clinical trials to help both themselves and
humanity or do they feel that they are victims, being used as
guinea pigs in an experiment over which they have little
control? In one study of 144 patients participating in
chemotherapy trials (Penman et al., 1984), the factors which
had led the patients to consent to randomisation were: a trust
in the physician, a belief that the treatment would work and
a fear that the disease would get worse without it. (This
implies that the patients were offered treatment vs supportive
care; this is uncommon in cancer trials now.) How often
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informed consent really is consent for randomisation and for
the chosen treatment remains unclear. Only 60% of patients
entered into a study at one centre (Cassileth et al., 1980)
understood the purpose of randomisation, and only 55%
could recall at least one complication or side-effect within 1
day after consent had been obtained.
A number of studies have attempted to compare the out-
come for patients treated in clinical trials with that of a
similar population of patients not entered onto research pro-
tocols (Antman et al., 1985; Davis et al., 1985; Karjalainen
and Palva, 1989; Stiller, 1992). These lines of data clearly
need to be interpreted with considerable caution because of
patient selection and because much of the work is based on
historical controls, but it is encouraging that most of these
studies suggest that patients fare better if treated in the
context of a properly conducted trial. Certainly, there is no
evidence that patients in treatment trials do worse.
Previous research (Mackillop et al., 1989) has indicated
that among lay individuals (never having had cancer) app-
roximately one-half think that they would agree to par-
ticipate in research protocols. One of the most commonly
stated reasons is that participation would help others in the
same situation in the future. However, this study was in a
population that was highly selective. The purpose of the
present survey was to explore patients' views about clinical
trials, with the aim of devising a strategy to encourage
patients to consider entering them. With this in mind, the
questionnaire attempted to determine which aspects of
clinical trials appeal to patients and which are a deterrent,
and whether their views on these issues influence their will-
ingness to participate. This report presents the findings from
the study, which was carried out in seven oncology centres in
the UK, as the first step in devising information that could
be provided to patients about trials in a neutral but infor-
mative manner (Angell, 1984).
Methods
Format
The pilot and study questionnaires were designed by
members of a small Working Group of the UKCCCR, con-
vened specifically to consider how to mobilise patients to
seek opportunities to participate in research studies.
A pilot questionnaire contained open-ended questions,
which it was hoped would provide indicators of the key
issues for patients in relation to participation in research
trials, which could then be developed as precoded items on
the subsequent questionnaire. The pilot questionnaire was
tested on 34 out-patients attending oncology clinics in the
UK; it was introduced and explained to the patient by the
clinic nurse. The only criteria for entry were that the patient
had been informed of his (or her) diagnosis, in order to avoid
distress in completing a questionnaire clearly related to
cancer, and could adequately understand English.
The study questionnaire was drawn up in the light of the
results from the pilot phase, and tested with the clinic nurses
to ensure that it was easily understood and contained perti-
nent items. It was based on a closed, multiple-choice format,
taking care to avoid leading questions, and was designed for
self-completion by patients. (The treatment was recorded by
the nurse if not known by the patient.) The entry criteria
were that the patient had been informed of their diagnosis
and could adequately understand English. Consecutive
patients were selected from clinics at the different centres,
except in Manchester where in-patients were asked to com-
plete the questionnaire.
The clinics participating in the study were at the following
hospitals: Western General and Longmore, Edinburgh; Beat-
son Oncology Centre, Glasgow; St Bartholomew's, Homer-
ton and Guys, London; Christie, Manchester, and Royal
Lancaster.
Questionnaire
Included in the letter explaining the survey and inviting
patients to participate was a description of a research trial.
(It was anticipated that most of the patients included in the
survey would not have taken part in a randomised trial.) The
questionnaire asked first about the type of specialist seen and
the route of referral to the specialist centre. Patients were
also asked about their level of knowledge about which doc-
tors treated cancer. The site of the patient's cancer was
recorded, and the treatment.
T1he main thrust of the questionnaire was to ascertain what
patients knew about research and which aspects of research
trials were considered appealing or unappealing based on the
free text responses to the pilot questionnaire (see Table I)
and - regardless of whether they were appealing or not -
which three of the items listed were considered the most
important. Finally, patients were asked to indicate whether
they would participate in a research trial, given the oppor-
tunity; if they were not willing, they were asked to explain
their reasons.
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Table I Appeal of the aspects ofclnical research lsted in the questionnaire
Greatly Slightly Slightly Greatly Non-
appealing appealing wappealig unappealing responents
Item ° % % % %
I Treatment decided by trial not 7 39 25 24 5
doctor
2 More tests/investigations carried 41 36 12 4 7
out
3 Contributes to research 75 12 4 3 6
knowledge and benefits
humanity
4 More likely to be treated by 83 7 3 1 6
doctors with specialist interest
in your type ofcancer
5 Greater chance of obtaining new 72 15 5 3 5
treatments
6 Treatments more likely to be 53 24 11 5 7
decided by a panel ofexperts
7 Progress monitored closely 80 12 1 1 6
8 Likely to obtain more information 75 16 0 3 6
about condition
9 Greater chance ofobtaining 27 28 24 15 6
experimental treatments
10 Don't choose treatment oneself 21 21 20 25 13M SIevi eta
Res
Patients
Seventy five were recruited; ofthese, 48% were male. The age
range was from 17 to 83 (mean 50.1; median 53).
Specialists
Patients in the survey were treated by medical oncologists
(80%), radiotherapists (12%), haematologists (4%), surgeons
(3%); one patient had seen a specialist previously but was
unable to specify the specialty. It was the first visit to this
particular clinic for 76%, although most had seen another
type of hospital doctor before being referred to the study
clinic: 56% had seen a surgeon, 27% a medical oncologist,
12% a radiotherapist, 7% a haematologist and 30% another
type ofdoctor (some patients had seen more than one type of
doctor before atending this clnic); 27% had been referred
dirctly by their general practitioner.
Twnour sites
The sites of the cancers being treated in the respondents were
gastrointestinal tract (including colorectal) (20%), lym-
phomas (20%), breast (20%), ovary (11/%), semnomas
(11%), lung (6%), myeloma (3%) and various other sites
(9%). Although one of the elgibility criteria was that
patients had been given their diagosis, only 91% replied
they were aware of the diagnosis.
Response to the questionnaire
The aspects of clinical trials that patients found most appeal-
ing (Table I) were that progress was monitored closely (80%
found this greatly appealing), that there was a greater chance
of being treated by a doctor with a special interest in the
patient's type of cancer (83% recorded this as greatly appeal-
ing), that taking part contributes to research knowledge and
benefits humanity (75% thought this greatly appealing) and
that patients in trials were likely to obtain more information
about their condition (scored as greatly appealing by 75% of
respondents). The aspects which were least appealing were
that treatment was decided by the trial rather than by the
doctor or individuaL and that there was a greater chance of
obtaining experimental treatments. This last response was
partcularly interestng, because the option 'greater chance of
obtaining new treatments' was scored as greatly appealng by
72% of respondents.
After being asked to rank items as greatly appealing,
slightly appealing, slightly unappealing, greatly unappealing,
patients were asked to identify which three of the ten items
were most important in order of rank. The results of this
choice showed that being looked after by a specialist was
regarded by 36% of patients as being the most important
aspect of clnical trials. Being given a chance of obtaining
new treatments, contributing to research knowledge and
benefiting huimanity were rated as important by about one-
third of patients. The other factors were ranked as most
important by only a small minority of patients (Table H).
Respondents were asked if they thought they would agree
to take part in a research trial for their illness. It was
explained that 'this would mean that you would be allocated
to either the new treatment or to standard treatments'. Forty-
two per cent said they would agree to take part and 10%
said they would not (or did not answer the question); 48%
were uncertain. Those who replied that they would not agree
to take part or were uncertain were asked for their reasons.
The respondents were most likely to select as their reason
'would prefer doctor to make the decision about the
treatment' (51%) and 'would worry about receiving new
treatment' (33%); 9% selected 'would prefer to be able to
choose treatment' and 7% gave a variety of other
free response reasons.
Tale II Aspectsofresearch trialsranked as thethree most important
(1-3inorderofimportance)bythe68patients(91%)whoindicated on
thequestions theirfirstchoice; 66patients(88%)alsogave theirsecond
and third choices
Most Important
1st 2nd 3rd
Item % No. % No. % No.
1 Treatment decided by 3 2 0 0 1 1
trial not doctor
2 More tests/ 3 2 5 4 3 2
investigations carried
out
3 Contributes to 21 16 7 5 12 9
research knowledge
and benefits
humanity
4 More ikely to be 36 27 17 13 5 4
treated by doctors
with specialist
interest in your type
ofcancer
5 Greaterchanceof 11 8 24 18 9 7
obtaining new
treatments
6 Treatments more 8 6 7 5 5 4
ikely to be decided
by a panel ofexperts
7 Progress monitored 3 2 13 10 25 19
closely
8 Likely to obtain more 5 4 9 7 20 15
information about
condition
9 Greaterchanceof 1 1 3 2 7 5
obtaining'
experimn«tal
treatments
10 Don'tchoos 0 0 3 2 0 0
treatment oneself
No. of respondents 68 66 66
The specialists taking part in this study were involved in the
non-surgical treatment of cancer. This does not detract from
the value of the survey since most clinical trials in cancer are
testing chemotherapy or radiotherapy.
It is an obvious paradox that although less than 5% of
patients are enered into clinical trials, 42% in this survey
said that they would agree to take part and only 10% said
they would refuse or did not answer this question. The
largest percentage (48%) indicated their uncertainty. The
second most quoted reason for this uncertainty was fear of
new treatment; this is presumably related to a concern that
new drugs are unknown entities with a high risk of failure or
unplasant side-effects. It is interesting that, when asked to
rank items as appealing or not 72% of respondents recorded
the 'greater chance of receiving new treatments' as greatly
appealing. Patients presumably have mixed feelings about
new treatments, seeing them as potentially exciting but also
as more frightening. Patients who enter clinical trials need to
know that new treatments may not be better than, and may
possibly not be as good as, standard treatments. However,
they also need to be reassured that by the time new
treatments are studied in randomised national trials, much
information about them has already been gained in phase I
and II trials. This should help to remove the fear of the
unknown. It would also counter the concerns expressed in
this survey that clinical trials may lead to a feeling of being
experimented on, and that they give neither the doctor nor
the patient any choice in the management of the disease.
The patients in this survey placed great emphasis on the
importance of being treated by a doctor who specialised in
their cancer, and they clearly found this to be reassuring.
However, many patients in the UK never see a cancer
specialist at any time in their treatment and this might be a
factor adding to the anxiety associated with a diagnosis of
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cancer. This may alter if the recently proposed changes in
cancer senrices are implemented. Also important to patients
is the closer monitoring that is often associated with trials;
this view might have an impact on patients' willingness to
participate in the increasingly common pragmatic trials
which manage to accrue the numbers of patients needed
because they do not demand extra tests and detailed data
collection. The majority ofpatients found the concept of new
treatments to be appealing, but were against being given
treatments described as experinental, presumably reflecting
how the treatment being tested is described, and emphasising
how dependent informed consent can be on the way inform-
ation is presented to the patient. More care in explaining
how much is known about the new treatment should help
reduce the fear of experimental therapy. Clinical researchers
need to review the way in which clinical trials are described
to potential participants, and it may be timely to undertake
research into alternative ways ofinviting patients with cancer
to volunteer for research protocols. It is encouraging that the
Department of Health has identified as one of the priorities
for research in cancer the issue ofincreasing recruitment into
trials.
There is accumulating evidence suggesting that patients in
clinical trials do better than those treated in an ad hoc
manner. In a study ofparticipants in trials for non-small-cell
lung cancer (Davis et al., 1985), which attempted to exclude
most factors which might have influenced survival when com-
paring a trial control group with a non-trial control group,
the authors postulated that there were at least four reasons
why trial patients did better. These were differences in (1)
preoperative evaluation, staging and subsequent follow-up;
(2) surgical technique; (3) placebo effects; and (4) patients'
motivation. It is unlikely that the differences will be entirely
artefactual arising from, for example, differences in patient
selection, or a guarantee period between surgery and ran-
domisation, although adhering to a defined surgical proce-
dure as has traditionally occurred for treatment trials may be
a factor influencing outcome.
Should such information about the benefits of trials be
included in the information given to patients? There is a need
to avoid unduly influencing patients by selling only the
positive aspects, and it has been suggested that it is unwise to
wait until patients are offered a trial before outlining the
issues involved (Baum, 1993). Simes et al. (1986) compared
two policies of obtaining consent: total disclosure of all
information or an individual approach tailored for each
patient. The study reported that patients in the total disc-
losure group were less willing to participate in clinical trials
according to the response to a questionnaire, although the
difference in actual refusal rates was not significant. What
was not reported was whether there was any difference in the
time taken to apply either policy. Since lack of time was the
major deterrent to participation identified in a recent survey
of clinicians participating in cancer clinical trials, an inform-
ation strategy which laid the ground work for a trial may be
of benefit.
The issue of informed consent (or informed dissent) con-
tinues to be thorny and will remain of considerable concern
to both patients and public alike for some considerable time.
It is too big an issue to be tackled sensibly here.
A recent publication from the Department of Health,
Assessing the Effects ofHealth Technologies (Advisory Group
for Health Technology Assessment, 1992), emphasises the
importance of clinical trials in identifying which new
treatments are an improvement over conventional ones, and
states that, when the optimal treatment is unk-nown, patients
should be treated within trials. It lacks, however, any com-
ment on how to increase patient recruitment into trials. At
present there is a disincentive for doctors to enter patients
into clinical trials because ofthe extra work involved for very
little associated benefit. Consideration must be given to pro-
viding incentives to encourage doctors to undertake this extra
work. The purchaser-provider arrangements may not include
an element for research, and this may be a major deter-
minant of whether a doctor is able to take part in research.
What should be included in any consideration of the costs of
clinical research are the costs associated with the uncont-
rolled use of therapies that have not been evaluated. A
relatively straightforward way to ease some of the burden
associated with clinical trials would be the introduction of a
central committee to review the ethics of proposed research;
one application to a central committee would be easier than
the multiple applications currently required. At the very least,
the introduction of a single form which could be used
nationally for submissions to local research ethics committees
would represent considerable progress in facilitating trials.
Within the health care system only limited resources are
available, and the extra financial costs that conducting
clinical trials imposes above the costs of providing 'best
standard care' have to be considered. In practice, the finan-
cial burden oftrials may be less than generally assumed since
many of the investigations associated with them should form
part of good clinical practice. Clearly data collection and
management require extra resources, but these can readily be
identified as research costs. It is timely for an analysis of the
extra costs of clinical trials to be carried out and for the
source of funding to cover these to be identified, so that
clinical trials do not deplete resources for routine patient
care. We welcome the recommendation of the Culyer Com-
mittee that this should be done (Culyer, 1994).
This study suggests that the majority of patients are either
enthusiastic about entering clinical trials or uncertain. Only a
small minority are unwilling to participate. A publicity cam-
paign to inform patients of the potential advantages of par-
ticipating in clinical trials, which also addresses their anx-
ieties, may have the effect of providing consumer pressure on
doctors to be more active in clinical research.
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